119 related articles for article (PubMed ID: 4727918)
41. Complement-dependent B-cell activation by cobra venom factor and other mitogens?
Dukor P; Schumann G; Gisler RH; Dierich M; König W; Hadding U; Bitter-Suermann D
J Exp Med; 1974 Feb; 139(2):337-54. PubMed ID: 4589989
[TBL] [Abstract][Full Text] [Related]
42. Complement inhibition significantly decreases red blood cell lysis in a rat model of acute intravascular hemolysis.
Shah TA; Mauriello CT; Hair PS; Sharp JA; Kumar PS; Lattanzio FA; Werner AL; Whitley PH; Maes LA; Cunnion KM; Krishna NK
Transfusion; 2014 Nov; 54(11):2892-900. PubMed ID: 24806146
[TBL] [Abstract][Full Text] [Related]
43. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
44. Oxygen-dependent circulation of sickle erythrocytes.
Castro O; Osbaldiston GW; Aponte L; Roth R; Orlin J; Finch SC
J Lab Clin Med; 1976 Nov; 88(5):732-44. PubMed ID: 988104
[TBL] [Abstract][Full Text] [Related]
45. Evidence for complement activation via the alternate pathway in skin diseases, I. Herpes gestationis, systemic lupus erythematosus, and bullous pemphigoid.
Provost TT; Tomasi TB
J Clin Invest; 1973 Jul; 52(7):1779-87. PubMed ID: 4352464
[TBL] [Abstract][Full Text] [Related]
46. Glomerular complement components in human glomerulonephritis.
Verroust PJ; Wilson CB; Cooper NR; Edgington TS; Dixon FJ
J Clin Invest; 1974 Jan; 53(1):77-84. PubMed ID: 4586873
[TBL] [Abstract][Full Text] [Related]
47. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets.
Taylor FB; Müller-Eberhard HJ
J Clin Invest; 1970 Nov; 49(11):2068-85. PubMed ID: 4248913
[TBL] [Abstract][Full Text] [Related]
48. Changes in the immunochemical properties of highly purified properdin in human serum.
Minta JO
J Immunol; 1975 Apr; 114(4):1415-21. PubMed ID: 123262
[TBL] [Abstract][Full Text] [Related]
49. The c3-activator system: an alternate pathway of complement activation.
Götze O; Müller-Eberhard HJ
J Exp Med; 1971 Sep; 134(3):90-108. PubMed ID: 19867385
[TBL] [Abstract][Full Text] [Related]
50. Formation and function of a complex of the C3 proactivator with a protein from cobra venom.
Cooper NR
J Exp Med; 1973 Feb; 137(2):451-60. PubMed ID: 4734404
[TBL] [Abstract][Full Text] [Related]
51. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
52. Activity levels of the alternate complement pathway in human pregnancy.
Brai M; Giambanco V; Waks H; Albano V; Osler AG
Acta Eur Fertil; 1974 Mar; 5(1):59-64. PubMed ID: 4844376
[No Abstract] [Full Text] [Related]
53. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
[TBL] [Abstract][Full Text] [Related]
54. Red cell stroma, a stable standard for assessment of platelet procoagulant release.
Rhoades P; Margolis J; Lovric VA
Pathology; 1979 Apr; 11(2):161-7. PubMed ID: 460941
[TBL] [Abstract][Full Text] [Related]
55. Blood coagulation changes in shock.
Garcia-Barreno P; Balibrea JL; Aparicio P
Surg Gynecol Obstet; 1978 Jul; 147(1):6-12. PubMed ID: 663810
[TBL] [Abstract][Full Text] [Related]
56. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
[TBL] [Abstract][Full Text] [Related]
57. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
Adam C; Williams DG; Peters DK
Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
[TBL] [Abstract][Full Text] [Related]
58. [The effect of endotoxin on coagulation mechanisms and on the development of disseminated intravascular coagulation].
Kase F; Kosina F
Bratisl Lek Listy; 1980 May; 73(5):634-40. PubMed ID: 6992951
[No Abstract] [Full Text] [Related]
59. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
McLean RH; Townsend K; Michael AF
Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation.
Rataj D; Werwitzke S; Haarmeijer B; Winkler M; Ramackers W; Petersen B; Niemann H; Wünsch A; Bähr A; Klymiuk N; Wolf E; Abicht JM; Ayares D; Tiede A
Xenotransplantation; 2016 Mar; 23(2):117-27. PubMed ID: 26773447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
